Morgan Stanley analyst Ricky Goldwasser said Catalent’s acquisition of Paragon Bioservices solidifies the company’s position in the biologics marketplace and further improves its growth profile. He now model fiscal 2020 revenue of $2.9B and EBITDA of $732M, up from $2.7B and $668M, respectively. Goldwasser raised his price target on Catalent shares to $50 from $46 following the deal announcement and keeps an Overweight rating on the stock.
https://thefly.com/landingPageNews.php?id=2893073
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.